Celldex Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Celldex Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 46% en 66.9% per jaar. De winst per aandeel zal naar verwachting groeien met 46.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -52.2% zijn.

Belangrijke informatie

46.0%

Groei van de winst

46.49%

Groei van de winst per aandeel

Biotechs winstgroei	25.4%
Inkomstengroei	66.9%
Toekomstig rendement op eigen vermogen	-52.22%
Dekking van analisten	Good
Laatst bijgewerkt	15 Jun 2026

Recente toekomstige groei-updates

Recent updates

Analyseartikel • Jun 19

Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data

Celldex Therapeutics (CLDX) is back in focus after presenting long term barzolvolimab data in chronic spontaneous urticaria and early CDX-622 results at a major allergy congress, spotlighting its mast cell targeted pipeline. See our latest analysis for Celldex Therapeutics. Celldex Therapeutics shares trade at US$32.43, with a year to date share price return of 20.07% and a 1 year total shareholder return of 58.20%. This suggests recent barzolvolimab and CDX-622 data are contributing to...

Analyseartikel • May 06

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Apr 22

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

Summary We initiate a Hold rating for Celldex Therapeutics due to uncertainties surrounding barzolvolimab's mid-2025 data readouts and potential market positioning challenges. Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with mixed competitive prospects. Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting downward pressure on valuation. Investment risks include trial failures, commercial uptake challenges, resource-intensive commercialization, potential side effects, and broader macroeconomic factors affecting funding and share price. Read the full article on Seeking Alpha

Analyseartikel • Jan 28

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • Jun 07

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Key Insights Celldex Therapeutics to hold its Annual General Meeting on 13th of June Total pay for CEO Anthony Marucci...

Analyseartikel • Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jul 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Winst- en omzetgroeiprognoses

NasdaqCM:CLDX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	166	-269	-196	-100	10
12/31/2027	12	-370	-281	-300	12
12/31/2026	3	-330	-281	-280	11
3/31/2026	1	-284	-226	-222	N/A
12/31/2025	2	-259	-214	-211	N/A
9/30/2025	3	-225	-182	-179	N/A
6/30/2025	6	-200	-188	-186	N/A
3/31/2025	8	-179	-173	-172	N/A
12/31/2024	7	-158	-160	-158	N/A
9/30/2024	10	-154	-160	-158	N/A
6/30/2024	8	-150	-123	-121	N/A
3/31/2024	6	-145	-121	-119	N/A
12/31/2023	7	-141	-109	-107	N/A
9/30/2023	4	-125	-98	-97	N/A
6/30/2023	3	-113	-114	-113	N/A
3/31/2023	3	-119	-110	-108	N/A
12/31/2022	2	-112	-106	-104	N/A
9/30/2022	1	-106	-98	-96	N/A
6/30/2022	1	-100	-79	-78	N/A
3/31/2022	4	-77	-69	-67	N/A
12/31/2021	5	-71	-62	-61	N/A
9/30/2021	8	-72	-53	-52	N/A
6/30/2021	9	-66	-48	-47	N/A
3/31/2021	5	-64	-48	-46	N/A
12/31/2020	7	-60	-42	-40	N/A
9/30/2020	5	-48	-48	-46	N/A
6/30/2020	4	-46	-47	-45	N/A
3/31/2020	5	-46	-46	-45	N/A
12/31/2019	4	-51	N/A	-46	N/A
9/30/2019	4	-50	N/A	-51	N/A
6/30/2019	5	-46	N/A	-54	N/A
3/31/2019	7	-50	N/A	-60	N/A
12/31/2018	10	-151	N/A	-75	N/A
9/30/2018	11	-146	N/A	-79	N/A
6/30/2018	14	-165	N/A	-89	N/A
3/31/2018	15	-177	N/A	-93	N/A
12/31/2017	13	-93	N/A	-100	N/A
9/30/2017	11	-121	N/A	-101	N/A
6/30/2017	9	-125	N/A	-100	N/A
3/31/2017	7	-128	N/A	-113	N/A
12/31/2016	7	-129	N/A	-113	N/A
9/30/2016	7	-129	N/A	-106	N/A
6/30/2016	6	-131	N/A	-110	N/A
3/31/2016	6	-132	N/A	-101	N/A
12/31/2015	5	-127	N/A	-99	N/A
9/30/2015	5	-126	N/A	-107	N/A
6/30/2015	5	-122	N/A	-106	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CLDX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CLDX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CLDX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CLDX ( 66.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.7% per jaar).

Hoge groei-inkomsten: De omzet van CLDX ( 66.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat CLDX binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/27 16:07
Aandelenkoers aan het einde van de dag	2026/06/26 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Celldex Therapeutics, Inc. wordt gevolgd door 22 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Etzer Darout	Barclays
Edward Nash	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.

Celldex Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$4.36 loss

Consensus revenue estimates fall by 19%

Price target decreased by 7.9% to US$53.85

Consensus revenue estimates fall by 18%

Price target decreased by 11% to US$57.58

Consensus revenue estimates increase by 15%, EPS downgraded

Recent updates

Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU

Celldex Reports Strong Progress in Mast Cell Therapies With Positive Trial Updates at EAACI 2026

Consensus EPS estimates upgraded to US$4.36 loss

New major risk - Revenue size

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Celldex Advances Barzolvolimab Trials With Strong Cash Position After Q1 Earnings Miss

Celldex Therapeutics, Inc., Annual General Meeting, Jun 25, 2026

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.005 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics, Inc. Presents Positive Data From Phase 2 Chronic Spontaneous Urticaria And Phase 2 Cold Urticaria And Symptomatic Dermographism Studies Demonstrating Rapid, Profound And Durable Improvements In Patient Quality Of Life At AAD 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Ret Treatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (Coldu) and Symptomatic Dermographism (Sd) Further Demonstrating First Exposure in Patients with Barzolvolimab

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (Csu) and Phase 2 Cold Urticaria (Coldu) and Symptomatic Dermographism (Sd) Studies Further Demonstrating First-In-Class and Best-Disease

Full year 2025 earnings: EPS and revenues miss analyst expectations

Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Chief Commercial Officer & Senior VP exercised options and sold US$490k worth of stock

Consensus revenue estimates fall by 19%

Third quarter 2025 earnings released: US$1.01 loss per share (vs US$0.64 loss in 3Q 2024)

Celldex Therapeutics, Inc. Announces Executive Changes

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study

Celldex Therapeutics, Inc. Announces Initial Positive Results from Phase 1 Trial of CDX-622

Price target decreased by 7.9% to US$53.85

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Celldex Therapeutics, Inc.(NasdaqCM:CLDX) dropped from Russell 2500 Growth Index

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Celldex Therapeutics Announces Election of Denice Torres to Its Board of Directors

Consensus revenue estimates fall by 18%

Price target decreased by 11% to US$57.58

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in This Difficult to Treat Disease

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Celldex Therapeutics, Inc., Annual General Meeting, Jun 05, 2025

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

Now 20% overvalued

Consensus revenue estimates increase by 15%, EPS downgraded

Celldex Therapeutics, Inc. Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life At Aaaai 2025

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Now 25% undervalued after recent price drop

New major risk - Revenue and earnings growth

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.